Compare FIZZ & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIZZ | IDYA |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 1991 | 2019 |
| Metric | FIZZ | IDYA |
|---|---|---|
| Price | $32.89 | $35.73 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $39.00 | ★ $49.42 |
| AVG Volume (30 Days) | 461.5K | ★ 897.0K |
| Earning Date | 12-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.66 | N/A |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $1,202,396,000.00 | $214,834,000.00 |
| Revenue This Year | $2.80 | $2,434.86 |
| Revenue Next Year | $2.19 | N/A |
| P/E Ratio | $17.51 | ★ N/A |
| Revenue Growth | 0.46 | ★ 5377.66 |
| 52 Week Low | $32.21 | $13.45 |
| 52 Week High | $50.51 | $36.61 |
| Indicator | FIZZ | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 65.05 |
| Support Level | $33.68 | $33.14 |
| Resistance Level | $35.88 | $36.61 |
| Average True Range (ATR) | 1.00 | 1.54 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 14.89 | 82.08 |
National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.